520 results on '"Ishigooka, Jun"'
Search Results
2. First-Generation Antipsychotics as a Bridge to Second-Generation Antipsychotics in the Japanese Pharmaceutical Industry: Mosapramine, Timiperone, Zotepine, and Nemonapride
3. From Perospirone and Blonanserin to Lurasidone
4. Several supplementary concepts for applied category-theoretical states over an extended Petri net using an example relating to genetic coding: Toward an abstract algebraic formulation of molecular/genetic biology
5. A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia
6. Effect of intermittent subchronic MK‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex
7. Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study
8. The effect of short or long sleep duration on quality of life and depression: an internet-based survey in Japan
9. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study
10. Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study
11. Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
12. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
13. From Perospirone and Blonanserin to Lurasidone
14. First-Generation Antipsychotics as a Bridge to Second-Generation Antipsychotics in the Japanese Pharmaceutical Industry: Mosapramine, Timiperone, Zotepine, and Nemonapride
15. Effects of chronic haloperidol treatment on the expression of fear memory and fear memory extinction in the cued fear‐conditioned rats.
16. A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia
17. Avoidance behavior associated with depressive symptoms in patients with implantable cardioverter defibrillators
18. Development of a new benzodiazepine hypnotics withdrawal symptom scale
19. Sensitivity and specificity of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) and the Intensive Care Delirium Screening Checklist (ICDSC) for detecting post-cardiac surgery delirium: A single-center study in Japan
20. Phase-delay in the light–dark cycle impairs clock gene expression and levels of serotonin, norepinephrine, and their metabolites in the mouse hippocampus and amygdala
21. Analysis of Clozapine Use and Safety by Using Comprehensive National Data From the Japanese Clozapine Patient Monitoring Service
22. A polymorphism in CCR1/CCR3 is associated with narcolepsy
23. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole
24. Effects of quetiapine on DNA methylation in neuroblastoma cells
25. Effect of Quetiapine on Per1, Per2, and Bmal1 Clock Gene Expression in the Mouse Amygdala and Hippocampus
26. Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
27. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study)
28. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study
29. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia : A 6-Week, Randomized Placebo-Controlled Study
30. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia : A 6-Week, Randomized Placebo-Controlled Study
31. Restless legs syndrome in hemodialysis patients: Prevalence and association to daytime functioning
32. Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
33. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
34. New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study
35. High prevalence of comorbidity of migraine in outpatients with panic disorder and effectiveness of psychopharmacotherapy for both disorders: A retrospective open label study
36. Corrigendum to “Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study”. [Journal of Affective Disorders 281 (2021) 160–167]
37. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
38. Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol
39. Predictors of efficacy in lithium augmentation for treatment-resistant depression
40. 32.7 Long-Term Safety and Efficacy of Blonanserin Oral Tablet (DSP-5423) in Adolescents With Schizophrenia: A 52-Week, Multicenter, Open-Label, Extension Study
41. Corrigendum to “Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study”. [Journal of Affective Disorders 281 (2021) 160–167]
42. Patient and Physician Perspectives of Depressive Symptoms and Expectations for Treatment Outcome: Results from a Web-Based Survey
43. Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
44. Dual orexin receptor antagonist (DORA-12) treatment affects the overall levels of Net/maoA mRNA expression in the hippocampus
45. New susceptibility variants to narcolepsy identified in HLA class II region
46. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats
47. Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
48. Additional file 1 of Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
49. Current state of hypnotic use disorders: Results of a survey using the Japanese version of Benzodiazepine Dependence Self-Report Questionnaire
50. Patient and Physician Perspectives of Depressive Symptoms and Expectations for Treatment Outcome: Results from a Web-Based Survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.